PARUCH, Kamil, Timothy GUZI, Michael DWYER, Ronald DOLL, Viyyoor GIRIVALLABHAN and Alan MALLAMS. Imidazopyrazines as Cyclin Dependent Kinase Inhibitors. 2004.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Imidazopyrazines as Cyclin Dependent Kinase Inhibitors
Name in Czech Imidazopyrazines as Cyclin Dependent Kinase Inhibitors
Authors PARUCH, Kamil (203 Czech Republic, guarantor), Timothy GUZI (840 United States of America), Michael DWYER (840 United States of America), Ronald DOLL (840 United States of America), Viyyoor GIRIVALLABHAN (840 United States of America) and Alan MALLAMS (840 United States of America).
Edition Number: WO 2004026877 A1, Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering-Plough, 2004.
Other information
Original language English
Type of outcome Patent
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/04:00035995
Organization unit Faculty of Science
Keywords (in Czech) cyclin dependent kinase; inhibitor; imidazopyrazine
Keywords in English cyclin dependent kinase; inhibitor; imidazopyrazine
Tags Cyclin dependent kinase, imidazopyrazine, inhibitor
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 25/6/2009 10:13.
Abstract
In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5 uM.
Abstract (in Czech)
viz Anotace
PrintDisplayed: 20/7/2024 11:29